WO2009059242A1 - A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use - Google Patents
A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use Download PDFInfo
- Publication number
- WO2009059242A1 WO2009059242A1 PCT/US2008/082139 US2008082139W WO2009059242A1 WO 2009059242 A1 WO2009059242 A1 WO 2009059242A1 US 2008082139 W US2008082139 W US 2008082139W WO 2009059242 A1 WO2009059242 A1 WO 2009059242A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- partial glycine
- glycine agonist
- levodopa
- agonist
- partial
- Prior art date
Links
- 230000036961 partial effect Effects 0.000 title claims abstract description 204
- 239000002431 glycine receptor agonist Substances 0.000 title claims abstract description 196
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 122
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 121
- 229960004502 levodopa Drugs 0.000 title claims abstract description 121
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 65
- 238000013270 controlled release Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000009472 formulation Methods 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
- 238000013268 sustained release Methods 0.000 claims abstract description 29
- 239000012730 sustained-release form Substances 0.000 claims abstract description 29
- 230000036470 plasma concentration Effects 0.000 claims abstract description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 20
- 210000004556 brain Anatomy 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims description 25
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 23
- 208000012661 Dyskinesia Diseases 0.000 claims description 21
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 19
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 14
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- -1 eleixirs Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 229960004205 carbidopa Drugs 0.000 claims description 8
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 claims description 7
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 7
- 229960000911 benserazide Drugs 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 claims description 7
- 208000010118 dystonia Diseases 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- HCKUBNLZMKAEIN-UHFFFAOYSA-N 3-amino-1-hydroxypyrrolidin-2-one Chemical compound NC1CCN(O)C1=O HCKUBNLZMKAEIN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 239000002304 perfume Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 238000007922 dissolution test Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 230000037058 blood plasma level Effects 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 8
- 239000007902 hard capsule Substances 0.000 claims 2
- 239000007901 soft capsule Substances 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
- 229940079593 drug Drugs 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 229960003638 dopamine Drugs 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 231100001274 therapeutic index Toxicity 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 10
- 229940127427 Glycine Agonists Drugs 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000013265 extended release Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000003701 inert diluent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 4
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030312 On and off phenomenon Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940052760 dopamine agonists Drugs 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000015592 Involuntary movements Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000035854 Drug effect decreased Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000005903 Manganese Poisoning Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940124533 adjunct drug Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940052036 carbidopa / levodopa Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Definitions
- the present disclosure relates to compositions and methods for the treatment of Parkinson's Disease and Parkinsonian related conditions.
- the present disclosure is more particularly related to controlled-release compositions which enhance the efficacy and reduce the side effects of levodopa in a controlled manner, and methods for using such compositions to promote stable relief from the symptoms of Parkinson disease.
- Parkinson's disease belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells.
- the four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination.
- PD usually affects people over the age of 50. Early symptoms of PD are subtle and occur gradually. In some people the disease progresses more quickly than in others.
- the shaking, or tremor which affects the majority of PD patients can begin to interfere with daily activities.
- Other symptoms can include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.
- levodopa-induced dyskinesia a side-effect called levodopa-induced dyskinesia
- a side-effect called levodopa-induced dyskinesia a side-effect called levodopa-induced dyskinesia
- a side-effect called levodopa-induced dyskinesia a side-effect called levodopa-induced dyskinesia
- 3) decreasing periods of drug effectiveness called the "wearing off” effect.
- Levodopa and other PD drugs can be used in combination or in series to prevent and/or ameliorate the symptoms of the disease, including administering dopamine agonists, enzyme inhibitors such as catechol-O-methyl transferase inhibitors, and monoamine oxidase type B (MAO-B) inhibitors and other drug classes, for example antivirals.
- dopamine agonists such as catechol-O-methyl transferase inhibitors, and monoamine oxidase type B (MAO-B) inhibitors and other drug classes, for example antivirals.
- enzyme inhibitors such as catechol-O-methyl transferase inhibitors, and monoamine oxidase type B (MAO-B) inhibitors and other drug classes, for example antivirals.
- MAO-B monoamine oxidase type B
- Dopamine agonists are a class of drugs that mimic the effect of dopamine in the brain. Dopamine agonists can be used alone in early Parkinson's disease and also in combination with levodopa. Side effects, for example, dyskinesias and dystonias are similar to those of levodopa although this class of drugs is more likely to cause hallucinations and sleepiness. Furthermore, these drugs have no affect on the therapeutic index of levodopa, i.e. the incidence of side-effects that are detrimental to the PD patient increase for a given levodopa dose over the course of treatment.
- Selegiline is a monoamine oxidase type B (MAO-B) inhibitor, often used in conjunction with levodopa to help prevent the breakdown of naturally produced dopamine and the dopamine produced by levodopa.
- MAO-B monoamine oxidase type B
- This drug inhibits the enzyme responsible for metabolizing dopamine in the brain.
- the efficacy of this inhibitor in the treatment of PD is dubious. Although clinicians believed that selegiline retarded the progression of Parkinson's disease, this now appears not to be true.
- Catechol-O-methyltransferase (COMT) inhibitors are used in combination with levodopa to prevent enzymes from breaking down dopamine in the liver and other organs.
- CCT Catechol-O-methyltransferase
- Amantadine is an antiviral drug that is often used to treat patients with late-stage Parkinson's disease, especially if they are having difficulty controlling involuntary movements caused by levodopa. Side effects can include swollen ankles and a purple mottling of the skin.
- Various pharmacokinetic and pharmacodynamic effects can lead to fluctuations of response to levodopa. These can include factors that affect gastric emptylng such as acidity, anticholinergics and food. Treatment-related changes in the central nervous system can also affect the pharmacodynamics of levodopa. Such factors can include reduced striatal storage of dopamine, damage to dopaminergic neurons by toxic byproducts of dopamine metabolism or altered dopamine receptors. The most frequent fluctuation a PD patient appears to experience is disruption in levodopa activity characterized by shorter periods of therapeutic benefit following each dose of levodopa. 'Wearing-off' is a regular and mostly predictable phenomenon linked with nigro-striatal system degeneration and reflects the extent of nigro-striatal dopamine system loss.
- sustained-release compositions can be preferred, by optimizing the kinetics of delivery, also increase patient compliance as patients are less likely to miss a dose with less frequent administration, particularly when a once- a-day dosage regimen is possible. This is particularly important for the intended patient population experiencing neurological sequelae in. addition to the Parkinsonian symptoms such as poor motor function. Less frequent administration of medication also increases patient convenience. Additionally, sustained-release formulations can reduce overall healthcare costs. Although the initial cost of sustained-release delivery systems may be greater than the costs associated with conventional delivery systems, average costs of extended treatment over time can be lower due to less frequent dosing, enhanced therapeutic benefit, reduced side-effects, and a reduction in the time required to dispense and administer the drug and monitor patient compliance.
- the present invention provides advantages over the prior art by allowing patients the freedom in taking as many doses of levodopa as needed without having to continuously take D-cycloserine to reduce the levodopa-induced side affects.
- sustained-release administration of D-cycloserine decreases the risk of toxicity.
- U.S. Pat. No. 7,160,913 to Schneider proposes the use of a partial glycine agonist to enhance the efficacy and therapeutic index of levodopa, In some compositions, the partial glycine agonist was administered with levodopa in a single composition.
- D-cycloserine and other partial glycine agonists have been shown to reduce the deleterious symptoms of PD while at the same time reducing the frequency and/or severity of levodopa-induced side effects in Parkinson's disease.
- fluctuations in partial glycine agonist dosing particularly when blood plasma levels spike above 30 ⁇ g/mL, can also induce undesirable side effects such as toxicity and worsening of levodopa side effects.
- compositions for the treatment of Parkinson's disease in a subject comprising a controlled release formulation having an immediate release component and a sustained release component.
- the controlled release formulation is adapted to release a partial glycine agonist according to an in vitro release profile when measured in a standard dissolution test apparatus, where the immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the total amount of the partial glycine agonist in the composition is released from the sustained release component during a second phase having a duration between 12 to about 24 hours.
- the partial glycine agonist is present in an amount effective when administered once daily to enhance the efficacy of levodopa concomitantly administered or to reduce the frequency or severity of side effects of the levodopa.
- the controlled release formulation includes one or more pharmaceutically acceptable excipients.
- the composition can comprise a controlled release formulation comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient.
- the composition upon initial administration of one dose, provides a mean plasma concentration of the partial glycine agonist of at least 10 ⁇ g/mL and not more than 30 ⁇ g/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 ⁇ g/mL for 12 - 24 hours.
- the partial glycine agonist is present in the composition in an amount effective to produce a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor for at least 12 to about 24 hours.
- a method for treating a subject for treating Parkinson's disease comprising administering levodopa to the patient at least once per day; and administering to the subject a once daily composition comprising a partial glycine agonist, formulated to provide a release profile, such that sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose administered together with or separately for at least 18 hours to about 24 hours after administration of the partial glycine agonist.
- kits comprising a partial glycine agonist in a controlled release formulation, and instructions for administering a high dose of a partial glycine agonist to a subject for the treatment of Parkinson's disease.
- the present invention provides methods and pharmaceutical compositions for reducing the severity or frequency of levodopa side effects with a once daily composition in patients with Parkinson's disease.
- Partial glycine agonists acting as antagonists also decrease neuronal excitotoxicity caused by excessive glutamate neurotransmission in the Parkinsonian brain. Decreasing neuronal excitotoxicity has antidepressant and anxiolytic effects, and can also have a positive effect on certain types of cognitive disorders. Depression and anxiety are common complications in subjects with PD. Thus, treatment of these complications is an added advantage to the administration of a partial glycine agonist with levodopa.
- methods of the invention are useful in the treatment of PD and Parkinsonian like disorders, wherein the subject in need of such treatment has been prescribed with a therapeutic formulation of levodopa, for example, an immediate release form oflevodopa which is taken three or more times a day.
- a subject suffering from PD can therefore be treated with levodopa and a once daily formulation of a controlled release form of a partial glycine agonist.
- Partial glycine agonists are known to those skilled in the art, and include D-cycloserine, 1- aminocyclopropaneearboxylic acid (ACPC) and (+)-3-Amino-1-hydroxypyrrolidin-2- one.
- a partial glycine agonist also includes substances which convert other substances into a partial glycine agonist in the body.
- a preferred partial glycine agonist is D-cycloserine.
- PD and related levodopa treatment side effects can be modulated by one or more partial glycine agonists formulated in a controlled release formulation, when administered in conjunction with levodopa, either in the same composition or when administered separately.
- Providing a therapeutic and effective dose of a partial glycine agonist also reduces the possibility of partial glycine agonist toxicity and insufficient dosing levels when compared to immediate release, multi dose regimens.
- an effective dose of a controlled release partial glycine agonist is a dose which produces a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor or acts as a functional antagonist at the NMDA receptor.
- a controlled release dose of a partial glycine agonist can be greater than 1 mg/kg body weight of the subject to be treated, for example at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg or at least 8 mg/kg partial glycine agonist made bioavailable over a period of from about 12 to 24 hours.
- at least 8 mg/kg partial glycine agonist is administered to the subject per unit dose, for example 1 to 12 mg/kg partial glycine agonist per unit dose made bioavailable over a period of from about 12 to 24 hours.
- the dose administered is one that is sufficient to maintain plasma levels between about 10 ⁇ g/mL and about 30 ⁇ g/ml for a period of 8 hours, for 12 hours, for 13 hours, for 14 hours, for 15 hours, for 16 hours, for 18 hours and not more than 24 hours.
- a "subject” is any mammal suffering from PD or exhibiting symptoms of PD.
- a subject can be a primate (e.g., human or macaque) or a rodent (e.g., mouse, rat or guinea pig), but most typically is a human subject.
- a primate e.g., human or macaque
- a rodent e.g., mouse, rat or guinea pig
- UPDRS Unified Parkinson's Disease Rating Scale
- Parkinson's disease includes PD of any etiology, including idiopathic PD, postencephalitic PD, PD resulting from chronic manganese poisoning or carbon monoxide poisoning, parkinsonism-dementia of Guam and hemiparkinsonism.
- PD also includes any neurological syndrome of undetermined etiology which a subject presents with neurological symptoms associated with a decrease in dopamine production or dopaminergic transmission in the brain.
- the composition to be used according to the present method has specific requirements with respect to its partial glycine agonist release properties. These properties can be defined in part by pharmacokinetic data for the controlled release composition comprising a partial glycine agonist that can be obtained experimentally, for example, from a statistically relevant number of test subjects according to pre-established and accepted pharmacokinetic protocol.
- the test subjects herein can be of the same species as the patients, i.e. a human, preferably adult, and preferably including a significant number of test subjects that are representative of the patients currently being treated for PD.
- the protocol can involve a single dose or once daily dosing for several days, usually at least 3-7 days.
- a dose, unit dosage, or doses used to provide pharmacokinetic data in test subjects should be similar to the once daily dose desired to be administered to the patient
- similar in the present context is meant equivalent, or sufficiently close that, by reasonable interpolation or extrapolation from the data, pharmacokinetic properties for the desired dose can be reasonable estimated.
- a composition having the in vitro release and/or in vivo pharmacokinetic parameters specified above is advantageous in having reduced potential to cause undesirable side effects related to partial glycine agonist toxicity that may be related to a combination of high C max and short T max , by comparison with other once-daily dosage forms.
- the incidence of side effects is no greater than with an immediate-release dosage form of a partial glycine agonist formulation administered in conjunction with levodopa in a three-five times daily regimen. More preferably, the incidence of levodopa use side effects is even lower than with such an immediate-release partial glycine agonist regimen. It is contemplated that these advantages become more pronounced with increase in daily dosage.
- the partial glycine agonist release profile provides sufficient partial glycine agonist in the brain of the subject to enhance efficacy or reduce the side effects of each levodopa dose concomitantly administered together with or separately of the partial glycine agonist for at least 18 to about 24 hours.
- the composition administered to PD subjects according to the present method provides a 8-24 hour profile of plasma partial glycine agonist concentration, averaged over the test subjects, that does not substantially exceed 30 ⁇ g/mL and does not substantially fall below about 10 ⁇ g/mL. It is an objective of the present invention to provide an effective dose of partial glycine agonist during the waking hours of the patient concurrently with levodopa administration.
- the plasma concentration of the partial glycine agonist during the patient's sleeping hours may deviate from the therapeutic range of approximately 10 ⁇ g/mL to 30 ⁇ g/mL.
- the plasma partial glycine agonist concentration neither substantially nor protractedly falls below about 1, about 5, about 7, about 9, or about 10 ⁇ g/ml. In various embodiments, the plasma partial glycine agonist concentration neither substantially nor appreciably exceeds about 40, about 37, about 35 or about 30 ⁇ g/ml. With respect to the terms “substantially” and “appreciably” in the present context, the following situations are illustrative. A concentration that is within about 20%, for example within about 20%, below a stated minimum or above a stated maximum is considered not to "substantially” fall below or exceed the stated minimum or maximum respectively.
- the plasma partial glycine agonist concentration, averaged over the test subjects does not substantially or appreciably fall below about 10 ⁇ g/mL and does not substantially or appreciably exceed about 30 ⁇ g/mL.
- the present invention illustratively provides examples of partial glycine agonist release from a controlled release formulation as measured in a standard in vitro dissolution test.
- the present invention is designed to be formulated with a specific pharmacokinetic profile wherein, with once daily administration of a controlled release formulation of a partial glycine agonist, plasma concentrations of the aforementioned agonist can remain within a narrow window as described above.
- the composition will typically be formulated wherein the release of a partial glycine agonist in an effective dose is still occurring at least about 8 hours, for example at least about 10 hours, at least about 12 hours, at least about 14 hours, at. least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, or at least about 24 hours.
- the pharmaceutical composition upon initial administration of one dose provides in the subject a mean plasma concentration of the partial glycine agonist of at least 10 ⁇ g/mL and not more than 30 ⁇ g/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 ⁇ g/mL for 12 - 24 hours.
- the partial glycine agonist can be present in an amount effective to produce a partial glycine agonist concentration in fee brain of a subject at which the partial glycine agonist antagonizes the glycine binding site or acts as a functional antagonist of the NMDA receptor for at least 12 -24 hours.
- a release profile is an example of a sustained profile or extended release profile.
- extended release has their commonly accepted meanings used in the field of pharmacy and pharmacokinetics.
- the kinetics of the extended release can be influenced by the choice of the delivery system, amount of the active ingredient, dissolution rate of the drug, compartment in which release occurs (e.g., with oral delivery systems, this is the gastrointestinal tract), absorption of drug from the site of release into the systemic circulation, drug distribution from the systemic circulation, etc.
- a once daily pharmaceutical composition can comprise a partial glycine agonist, wherein the composition also includes a controlled release matrix or coating portion comprising a partial glycine agonist, a sustained release carrier, and at least one pharmaceutically acceptable excipient.
- the composition upon initial administration of one dose can provide a mean plasma concentration of the partial glycine agonist of at least 10 ⁇ g/mL and not more than 30 ⁇ g/mL within one hour of administration and continues to provide a mean plasma concentration of Hie partial glycine agonist of not more than 30 ⁇ g/mL for 12 - 18 hours.
- the partial glycine agonist is present and upon release, the partial glycine agonist dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa.
- a once daily pharmaceutical composition for the treatment of PD in a patient comprises a controlled release formulation having an immediate release component and a sustained release component.
- the formulation is adapted to release a partial glycine agonist according to an in vitro release profile when measured in a standard dissolution test apparatus, i.e. in a U.S.P.
- the partial glycine agonist can be present in an amount effective when administered once daily to enhance the efficacy of levodopa concomitantly administered with or separately or to reduce the frequency or severity of side effects of the levodopa.
- the controlled release formulation can include one or more pharmaceutically acceptable excipients.
- the pharmaceutical composition can also contain one or more excipients which can include one or more of carriers, wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidant and mixtures or combinations thereof.
- a controlled release formulation can comprise a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient
- the composition upon initial administration of one dose can provide a mean plasma concentration of the partial glycine agonist of at least 10 ⁇ g/mL and not more than 30 ⁇ g/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 ⁇ g/mL for 12 - 24 hours.
- the partial glycine agonist dose present in the composition when released in the subject, can provide an amount effective to produce a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor or acts as a functional antagonist of the NMDA receptor for at least 12, or about 14, or about 16, or about 18, or about 20, or about 22, or about 24 hours.
- the partial glycine agonist is present in a dose that when made bioavailable in the subject, is effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa.
- the controlled release partial glycine agonist can be administered in conjunction with levodopa, and can be administered together with the partial glycine agonist or taken separately.
- the controlled release partial glycine agonist can be taken at the same time as the levodopa or before taking levodopa.
- the levodopa can be ingested 1 hour, 2 hours, 3 hours or up to 4 hours after the administration of the controlled release partial glycine agonist.
- the levodopa and partial glycine agonist can optionally be administered with a peripheral dopa decarboxylase inhibitor, such as carbidopa or benserazide.
- peripheral dopa decarboxylase inhibitor to be administered to a subject.
- 10 mg of carbidopa or 15 mg of benserazide can be given 2-3 times daily with levodopa to the average adult human.
- Carbidopa or benserazide dosage can be adjusted upward daily until the desired effect is seen.
- Combined carbidopa/levodopa formulations are available commercially, for example, from Bristol Meyers Squibb Co,, Princeton, N.J., as SinemetRTM.
- the present disclosure provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of a partial glycine agonist described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
- the controlled release pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.
- parenteral administration for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension of sustained-release formulation
- topical application for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; sublingual; ocular; transdermal; or nasal.
- the compositions of the present invention comprise one or more controlled release components.
- the controlled release properties exhibit an extended or sustained release pharmacokinetic profile.
- the compositions may contain one or more controlled release materials, illustratively selected from two formulation components having different release characteristics.
- a composition can comprise a first formulation component comprising a partial glycine agonist exhibiting a first release profile and a second formulation component comprising the same or different partial glycine agonist exhibiting a second release profile.
- the first release profile can be an immediate release profile and the second release profile can be an extended or sustained release profile.
- the composition comprises a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 ⁇ g/mL and not more than 30 ⁇ g/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 ⁇ g/mL for at least 12 hours to about 24 hours.
- the partial glycine agonist is present in the pharmaceutical composition in a dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa in a Parkinson's subject treated with levodopa.
- the immediate and sustained release components can be more or less intimately co-mixed or blended, or alternatively can form spatially distinct zones of the dosage form.
- An illustrative composition has spatially distinct zones comprising a core and a mantle surrounding the core.
- the mantle can comprise a partial glycine agonist exhibiting an immediate release profile and the core can comprise the same or different partial glycine agonist exhibiting a sustained release profile.
- compositions have spatially distinct zones comprising at least two layers.
- An example of such a composition is a bilayer tablet, wherein one layer, an immediate release component, can comprise a partial glycine agonist exhibiting an immediate release profile and the other sustained release component layer comprises the same or different partial glycine agonist exhibiting an sustained release profile.
- the composition comprises an immediate release and sustained release formulation components as described above, which comprise particles of a first and second kind respectively.
- the particles of the first kind can exhibit an immediate release profile and the particles of the second kind can exhibit a sustained release profile.
- the particles of the second kind comprise a core comprising the partial glycine agonist and a sustained and/or delayed release coating comprising the same or different partial glycine agonist surrounding the core.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically-acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e. g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
- manufacturing aid e. g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid
- solvent encapsulating material involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other components and agents of the formulation and not deleterious to the patient after administration.
- pharmaceutically-acceptable carriers can include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; any polyol, such as, but not limited to, glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; iso
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin
- a formulation of the present disclosure comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e. g., bile acids, and polymeric carriers, e. g., polyesters and polyanhydrides.
- an aforementioned formulation renders orally bioavailable a compound of the present disclosure.
- formulations are prepared by uniformly and mixing with a partial glycine agonist with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product
- Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges, powders, granules, or as a solution or a suspension in an aqueous or non- aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) each containing an effective amount of a partial glycine agonist as an active ingredient.
- a controlled release partial glycine agonist formulation of the present disclosure may also be administered as a bolus, electuary or paste.
- the partial glycine agonist is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as glycerol and paraffin; absorption accelerators, such as quaternary ammonium compounds and surfactants
- compositions can also comprise buffering agents.
- Solid compositions of controlled release partial glycine agonist formulations can also be used as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
- the present controlled release pharmaceutical compositions can be formulated so as to provide immediate, sustained, delayed, pulsed, biphasic release of a partial glycine agonist using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- the compositions may be prepared for immediate release, e.g., freeze-dried.
- the compositions can be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- the compositions can also optionally contain opacifying agents and may be of a composition that they release the partial glycine agonist or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
- the partial glycine agonist can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- compositions intended for oral use can be prepared according to any method commonly known in the art.
- the pharmaceutical compositions of the present disclosure can contain one or more agents selected from the group consisting non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients include, for example, an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
- the tablets may be uncoated or they may be coated by known techniques for elegance or to delay release of the active ingredients.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the partial glycine agonist is mixed with an inert diluent and a controlled and/or immediate release matrix or coating.
- Liquid dosage forms for oral administration of the compounds of the disclosure can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- the oral compositions can also include adjuvants such as we
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the partial glycine agonist can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellents which may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstitut ⁇ d hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a partial glycine agonist of the present disclosure to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- compositions of the present disclosure can be suitable for parenteral administration comprising a partial glycine agonist in a controlled release formulation in combination with one or more pharmaceutically- acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- compositions comprising a partial glycine agonist, for example by using the principles set forth in Remington's Pharmaceutical Science, 18th Edition (Alphonso Gennaro, ed.), Mack Publishing Co., Easton, Pa, 1990.
- Preferred pharmaceutical compositions of the present disclosure comprise a partial glycine agonist in a controlled release form.
- compositions of the present disclosure may be given enterally, illustratively orally, parenterally, topically, or rectally. They are of course provided in forms suitable for each administration route. For example, they can be administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
- a partial glycine agonist may be administered to humans and other animals, including rats, mice, rabbits , dogs, cats, non-human primates, and monkeys for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- any suitable route of administration including orally, nasally, as by, for example, a spray, rectally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present disclosure which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
- a suitable daily dose of a partial glycine agonist contained within a controlled release formulation will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect i.e. a dose which produces a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor.
- an effective dose can be a dose of a partial glycine agonist wherein the plasma levels of the partial glycine agonist in the patient is between about lO ⁇ g/raL and about 30 ⁇ g/mL for at least about 12 hours to at least about 24 hours. Such an effective dose will generally depend upon the factors described above.
- oral, intravenous, and subcutaneous doses of the controlled release partial glycine agonist of the present disclosure for a patient when used for the desired thereapeutic effects, will range from about 1 to about 12 mg per kilogram of body weight per dose of D-cycloserine or a therapeutically equivalent amount of partial glycine agonist other than D-cycloserine.
- the dosage of partial glycine agonist can be about 1 mg to about 12 mg of D-cycloserine per kg body weight of the subject per dose or equivalents thereof.
- the once daily pharmaceutical composition containing the controlled release partial glycine agonist formulation can be concomitantly administered with at least one dose of levodopa.
- the effective daily dose of levodopa may be administered as two, three, four, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- Preferred dosing for the levodopa is one or more administrations per day, optionally in combination with carbidopa and/or a peripheral dopa carboxylase such as benserazide.
- the present disclosure provides pharmaceutically acceptable compositions which comprise a controlled release formulation adapted to release a partial glycine agonist according to a single sustained release profile or a dual profile having two different release component phases of dissolution when measured in a U.S.P. type I dissolution apparatus in an acidic pH medium at 100 r.p.m., 37°C, where the immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the total amount of the partial glycine agonist in the composition is released from the sustained release component during a second phase having a duration between 12 to about 24 hours;
- the partial glycine agonist is administered in a dose effective to enhance the efficacy of levodopa or to reduce the frequency or severity of side effects of the levodopa,
- a method for treating Parkinson's disease in a patient comprising: administering levodopa to the patient at least once per day; and administering to the patient a once daily composition comprising a single unit dose partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose administered together with or separately for up to 18 hours after administration of the partial glycine agonist.
- Increasing the duration of effect of a levodopa dose with a therapeutic dose of a controlled release partial glycine agonist allows one to give fewer levodopa doses, avoid side effects, reduce the severity of the side effects of levodopa, or to reduce the levodopa standard dose, but still achieve the same therapeutic effect. This is particularly advantageous, because giving fewer or reduced levodopa doses to a subject with PD delays the point at which levodopa becomes ineffective.
- Administering a pharmaceutical composition comprising a controlled release formulation of partial glycine agonist also reduces the frequency or severity of levodopa-induced side effects, such as dyskinesias and dystonias.
- One skilled in the art can readily determine whether the frequency or severity of levodopa-induced dyskinesias is reduced by using any suitable technique for the clinical assessment of involuntary movements in subjects with PD.
- the frequency and severity of levodopa-induced dyskinesias can be assessed using the Abnormal Involuntary Movement Scale (AIMS) or similar rating of dyskinesia.
- AIMS Abnormal Involuntary Movement Scale
- assessment of subjects undergoing levodopa therapy with high dose partial glycine agonist are subjected to a six-week trial.
- subjects fill out a detailed diary with regard to the frequency or duration of dyskinesias and severity of any dyskinesias and assess daily function according to the following scales:
- Dyskinesia Intensity 0-without dyskinesia; 1-mild dyskinesia; 2- medium dyskinesia; 3-severe dyskinesia.
- Rating of Daily Function 1-improvement of daily function as compared to the basic condition; 2-no improvement in daily function; 3-deterioration of daily function as compared to the basic condition.
- a reduction in the daily AIMS scores duration of dyskinseias during the course of the trial indicates that the frequency and severity of dyskinesias are being reduced.
- AIMS scores obtained after administration of levodopa and high dose partial glycine agonist to a subject can be compared to AIMS (or similar test) scores obtained for the subject prior to treatment with high dose partial glycine agonist.
- frequency or severity of levodopa-induced dystonias is reduced by using any suitable technique for the clinical assessment of involuntary, sustained muscle contraction in subjects with PD.
- frequency or severity of dystonias can be determined by clinical observation of the subject, including reflex studies, or by techniques such as electromyography (EMG) or nerve conduction velocity tests.
- EMG electromyography
- the present disclosure also provides a method for increasing the therapeutic index of levodopa in a subject being treated for Parkinson's disease, comprising administering levodopa and a pharmaceutical composition comprising a controlled release formulation comprising partial glycine agonist in an effective dose to the subject.
- therapeutic index refers to a quantitative measure of the selectivity of a drug when a therapeutic effect ("E") and a toxic effect ("T") are being compared.
- the therapeutic index can then be calculated as ED 50 /TD 50 , at some arbitrary level of response observed in a subject receiving the drug.
- the ED 50 is the dose required to generate the desired intensity of therapeutic effect in 50% of the subjects tested.
- the TD 50 is the dose required to generate the toxic effect in 50% of the subjects tested.
- the therapeutic index is a useful indicator of the benefit versus adverse effect of a drug. Those drugs which have a high therapeutic index can be administered over a wide range of effective doses without incurring significant adverse events. Conversely, drugs having a small therapeutic index can be administered over a small range of effective doses without incurring significant adverse events.
- the therapeutic index of levodopa lessens over time with chronic administration.
- a pharmaceutical composition comprising a controlled release formulation of partial glycine agonist can increase the efficacy of levodopa while also reducing toxic side effects.
- the therapeutic index of levodopa is increased by administration of a controlled release dose of a partial glycine agonist over a period of 12 to about 24 hours.
- techniques for determining whether the efficacy of levodopa has increased, and whether toxic side effects of levodopa have been reduced are within the skill in the art. Suitable effective doses of the partial glycine agonist and suitable routes of administration are as described above.
- Substances which inhibit peripheral dopa decarboxylase e.g., carbidopa or benserazide
- the present disclosure provides a method of treating PD in a subject, comprising administering to a subject in need of such treatment a partial glycine agonist in a controlled release formulation having an immediate release component and a sustained release component.
- a partial glycine agonist in a controlled release formulation having an immediate release component and a sustained release component.
- altered NMDA receptor transmission can be involved in abnormal basal ganglia activity in PD and is involved in levodopa-related treatment complications such as wearing off and dyskinesia.
- Partial glycine agonists acting as non-selective antagonists of the NMDA receptor can correct this altered NMDA receptor transmission.
- Suitable and effective doses of the partial glycine agonist and suitable routes of administration are as described above.
- the present disclosure also provides a kit comprising a controlled release formulation comprising a partial glycine agonist and instructions for administering a sustained release or biphasic release profile of the partial glycine agonist to a subject suffering from PD.
- the instructions can specify mat the partial glycine agonist is administered with or without levodopa.
- the instructions specify that the partial glycine agonist is administered with levodopa, and that more than one dose of levodopa per day is required to maintain thereapeutic benefit of the levodopa.
- the instructions can also specify that the partial glycine agonist can. be administered with a peripheral dopa decarboxylase inhibitor such as carbidopa or benserazide.
- the kit further comprises levodopa. in another embodiment, the kit further comprises levodopa and a peripheral dopa decarboxylase inhibitor.
- the kit comprises a controlled release formulation comprising partial glycine agonist and levodopa in separate pharmaceutical compositions, in which the amount of partial glycine agonist is sufficient to sustain a plasma level of 10, 15, 20, 25, or 30 ⁇ g/mL partial glycine agonist while the patient is awake for at least 12 hours but no more than 16 hours within a 24 hour period.
- the single-dose pharmaceutical composition can deliver at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg or at least 8 mg/kg, for example 8 to 12 mg/kg, partial glycine agonist to the subject over a period of at least 12 hours and generally no more than 24 hours maintaining the plasma concentration of partial glycine agonist in the subject constant or in a dual (immediate and sustained) release profile wherein there is a spike in the concentration of the partial glycine agonist wherein 0-30 % of the total dose of the partial glycine agonist is released in the first 60 minutes and the balance of the total partial glycine agonist present is released in a constant and sustained fashion over a period of 11 to 23 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition comprises partial glycine agonist in a controlled release formulation for once a day administration to subjects with Parkinson's disease. The composition includes a controlled release material comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 - 16 hours. The partial glycine agonist is administered in a dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa. A method for treating Parkinson's disease in a subject comprises administering levodopa to the patient at least once per day and administering to the patient a once daily composition including a partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose for up to 16 hours after administration of the partial glycine agonist.
Description
A CONTROLLED-RELEASE PARTIAL GLYCINE AGONIST COMPOSITION FOR USE WITH LEVODOPA IN PARKINSON'S DISEASE AND METHOD OF
USE
FIELD OF THE INVENTION
[0001] The present disclosure relates to compositions and methods for the treatment of Parkinson's Disease and Parkinsonian related conditions. The present disclosure is more particularly related to controlled-release compositions which enhance the efficacy and reduce the side effects of levodopa in a controlled manner, and methods for using such compositions to promote stable relief from the symptoms of Parkinson disease.
BACKGROUND OF THE INVENTION
[0002] The statements in this section merely provide background information related to the present disclosure and cannot constitute prior art. Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients can have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 50. Early symptoms of PD are subtle and occur gradually. In some people the disease progresses more quickly than in others. As the disease progresses, the shaking, or tremor, which affects the majority of PD patients can begin to interfere with daily activities. Other
symptoms can include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.
[0003] Currently, the most effective treatment for PD is the combination of levodopa and carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Nerve cells can use levodopa to make dopamine and replenish the brain's dwindling supply. The drug levodopa is the standard treatment for Parkinson's disease. However, after four to five years of taking levodopa, more than 75 percent of patients can experience disabling motor fluctuations due to 1) unpredictable changes in drug effectiveness, called the on-off effect; 2) sudden and unpredictable changes in movement, a side-effect called levodopa-induced dyskinesia; and/or 3) decreasing periods of drug effectiveness, called the "wearing off" effect. These complications compromise long-term treatment. Chronic use of levodopa also causes other serious side-effects, including dystonia, drop in blood pressure, hallucinations and nausea. Levodopa and other PD drugs can be used in combination or in series to prevent and/or ameliorate the symptoms of the disease, including administering dopamine agonists, enzyme inhibitors such as catechol-O-methyl transferase inhibitors, and monoamine oxidase type B (MAO-B) inhibitors and other drug classes, for example antivirals.
[0004] Dopamine agonists are a class of drugs that mimic the effect of dopamine in the brain. Dopamine agonists can be used alone in early Parkinson's disease and also in combination with levodopa. Side effects, for example, dyskinesias and dystonias are similar to those of levodopa although this class of drugs is more likely to cause hallucinations and sleepiness. Furthermore, these drugs have no affect on the therapeutic index of levodopa, i.e. the incidence of side-effects that are
detrimental to the PD patient increase for a given levodopa dose over the course of treatment.
[0005] Selegiline is a monoamine oxidase type B (MAO-B) inhibitor, often used in conjunction with levodopa to help prevent the breakdown of naturally produced dopamine and the dopamine produced by levodopa. This drug inhibits the enzyme responsible for metabolizing dopamine in the brain. The efficacy of this inhibitor in the treatment of PD is dubious. Although clinicians believed that selegiline retarded the progression of Parkinson's disease, this now appears not to be true.
[0006] Catechol-O-methyltransferase (COMT) inhibitors are used in combination with levodopa to prevent enzymes from breaking down dopamine in the liver and other organs. Research suggests that some of these drugs, such as tolcapone, can cause liver damage and liver failure. As a result, these drugs are used primarily when the patient is not well responding to other treatments, particularly levodopa.
[0007] Amantadine is an antiviral drug that is often used to treat patients with late-stage Parkinson's disease, especially if they are having difficulty controlling involuntary movements caused by levodopa. Side effects can include swollen ankles and a purple mottling of the skin.
[0008] Various pharmacokinetic and pharmacodynamic effects can lead to fluctuations of response to levodopa. These can include factors that affect gastric emptylng such as acidity, anticholinergics and food. Treatment-related changes in the central nervous system can also affect the pharmacodynamics of levodopa. Such factors can include reduced striatal storage of dopamine, damage to dopaminergic neurons by toxic byproducts of dopamine metabolism or altered dopamine receptors. The most frequent fluctuation a PD patient appears to experience is disruption in
levodopa activity characterized by shorter periods of therapeutic benefit following each dose of levodopa. 'Wearing-off' is a regular and mostly predictable phenomenon linked with nigro-striatal system degeneration and reflects the extent of nigro-striatal dopamine system loss.
[0009] During the course of disease, PD patients experiencing further neuronal degeneration, and have relatively predictable 'wearing-off fluctuations. Eventually, these fluctuations become less predictable and can progress to the abrupt and unpredictable 'on/off' phenomenon, which is characterized by sudden and unpredictable shifts between the 'on' and 'off states, together with dyskinesias, dystonias and other adverse side effects of levodopa therapy. During this phase, patients undergoing levodopa treatment can display sensory, psychiatric and autonomic symptoms. They can complain of pain, paresthesias, sweating, constipation or shortness of breath, generally during the 'off times. 'On/off' fluctuations appear to be associated with a lowered threshold for dyskinesias. Management of motor fluctuations can involve delicate balancing of levodopa regimen, doses and adjunct drugs.
[0010] Therefore, sustained-release compositions can be preferred, by optimizing the kinetics of delivery, also increase patient compliance as patients are less likely to miss a dose with less frequent administration, particularly when a once- a-day dosage regimen is possible. This is particularly important for the intended patient population experiencing neurological sequelae in. addition to the Parkinsonian symptoms such as poor motor function. Less frequent administration of medication also increases patient convenience. Additionally, sustained-release formulations can reduce overall healthcare costs. Although the initial cost of sustained-release delivery systems may be greater than the costs associated with conventional delivery systems,
average costs of extended treatment over time can be lower due to less frequent dosing, enhanced therapeutic benefit, reduced side-effects, and a reduction in the time required to dispense and administer the drug and monitor patient compliance. Accordingly, the present invention provides advantages over the prior art by allowing patients the freedom in taking as many doses of levodopa as needed without having to continuously take D-cycloserine to reduce the levodopa-induced side affects. As discussed below, sustained-release administration of D-cycloserine decreases the risk of toxicity.
[0011] Schneider (U.S. Pat. No. 6,551,993) discuses the use of partial glycine agonists to treat cognitive dysfunction in a subject having schizophrenia or PD by administering a therapeutically effective dose of a partial glycine agonist to the glycine modulatory site of the NMDA receptor. However, there is no disclosure to suggest the use of a partial glycine agonist to reduce the severity or frequency of long- term side effects of levodopa use.
[0012] U.S. Pat. No. 7,160,913 to Schneider proposes the use of a partial glycine agonist to enhance the efficacy and therapeutic index of levodopa, In some compositions, the partial glycine agonist was administered with levodopa in a single composition.
[0013] D-cycloserine and other partial glycine agonists have been shown to reduce the deleterious symptoms of PD while at the same time reducing the frequency and/or severity of levodopa-induced side effects in Parkinson's disease. However, fluctuations in partial glycine agonist dosing, particularly when blood plasma levels spike above 30 μg/mL, can also induce undesirable side effects such as toxicity and worsening of levodopa side effects. A need exists therefore, to provide a therapeutic regimen to maintain the long-duration levodopa response and reduce or
avoid the appearance of daily motor fluctuations including dyskinesias due to long term levodopa therapy using partial glycine agonists.
SUMMARY OF THE INVENTION
[0014] There is now provided a pharmaceutical composition for the treatment of Parkinson's disease in a subject, said composition comprising a controlled release formulation having an immediate release component and a sustained release component. The controlled release formulation is adapted to release a partial glycine agonist according to an in vitro release profile when measured in a standard dissolution test apparatus, where the immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the total amount of the partial glycine agonist in the composition is released from the sustained release component during a second phase having a duration between 12 to about 24 hours. The partial glycine agonist is present in an amount effective when administered once daily to enhance the efficacy of levodopa concomitantly administered or to reduce the frequency or severity of side effects of the levodopa. The controlled release formulation includes one or more pharmaceutically acceptable excipients.
[0015] In one embodiment, the composition can comprise a controlled release formulation comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient. The composition, upon initial administration of one dose, provides a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 - 24 hours. The partial glycine agonist is present in the composition in an amount effective to produce a partial glycine agonist
concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor for at least 12 to about 24 hours.
[0016] There is further provided a method for treating a subject for treating Parkinson's disease in comprising administering levodopa to the patient at least once per day; and administering to the subject a once daily composition comprising a partial glycine agonist, formulated to provide a release profile, such that sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose administered together with or separately for at least 18 hours to about 24 hours after administration of the partial glycine agonist.
[0017] There is still further provided a kit comprising a partial glycine agonist in a controlled release formulation, and instructions for administering a high dose of a partial glycine agonist to a subject for the treatment of Parkinson's disease.
[0018] Further areas of applicability will become apparent from the description provided herein. It should be understood that the description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
DETAILED DESCRIPTION
[0019] The present invention provides methods and pharmaceutical compositions for reducing the severity or frequency of levodopa side effects with a once daily composition in patients with Parkinson's disease.
[0020] It has now been found that administering a controlled dose of a partial glycine agonist to subjects undergoing levodopa therapy enhances the duration of effect of levodopa (i.e., prevents the "wearing off" phenomenon), provides a
greater therapeutic effect than levodopa alone, and decreases the severity and frequency of side effects that result from long-term use oflevodopa. Treatment of PD patients with a high dose of a partial glycine agonist and levodopa also allows for a decrease in levodopa dosage, which helps delay the wearing-off effect and decreases levodopa-induced side effects as shown by Schneider, J., U.S. Pat. No. 7,160,913, which is incorporated by reference herein.
[0021] Partial glycine agonists acting as antagonists also decrease neuronal excitotoxicity caused by excessive glutamate neurotransmission in the Parkinsonian brain. Decreasing neuronal excitotoxicity has antidepressant and anxiolytic effects, and can also have a positive effect on certain types of cognitive disorders. Depression and anxiety are common complications in subjects with PD. Thus, treatment of these complications is an added advantage to the administration of a partial glycine agonist with levodopa.
[0022] More particularly, methods of the invention are useful in the treatment of PD and Parkinsonian like disorders, wherein the subject in need of such treatment has been prescribed with a therapeutic formulation of levodopa, for example, an immediate release form oflevodopa which is taken three or more times a day. A subject suffering from PD can therefore be treated with levodopa and a once daily formulation of a controlled release form of a partial glycine agonist. Partial glycine agonists are known to those skilled in the art, and include D-cycloserine, 1- aminocyclopropaneearboxylic acid (ACPC) and (+)-3-Amino-1-hydroxypyrrolidin-2- one. As used herein, a partial glycine agonist also includes substances which convert other substances into a partial glycine agonist in the body. A preferred partial glycine agonist is D-cycloserine.
[0023] In some embodiments, PD and related levodopa treatment side effects can be modulated by one or more partial glycine agonists formulated in a controlled release formulation, when administered in conjunction with levodopa, either in the same composition or when administered separately. Providing a therapeutic and effective dose of a partial glycine agonist also reduces the possibility of partial glycine agonist toxicity and insufficient dosing levels when compared to immediate release, multi dose regimens.
[0024] The terms "treat", "treating" and "treatment" herein will be understood, except where the context demands otherwise, to encompass prophylactic administration to a patient experiencing symptoms of PD and which is undergoing levodopa therapy for the daily relief of PD symptoms and the frequency or severity of the side effects of levodopa therapy.
[0025] As used herein, an effective dose of a controlled release partial glycine agonist is a dose which produces a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor or acts as a functional antagonist at the NMDA receptor. Preferably, a controlled release dose of a partial glycine agonist can be greater than 1 mg/kg body weight of the subject to be treated, for example at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg or at least 8 mg/kg partial glycine agonist made bioavailable over a period of from about 12 to 24 hours. Preferably, at least 8 mg/kg partial glycine agonist is administered to the subject per unit dose, for example 1 to 12 mg/kg partial glycine agonist per unit dose made bioavailable over a period of from about 12 to 24 hours. In some embodiments, the dose administered is one that is sufficient to maintain plasma levels between about 10 μg/mL and about 30 μg/ml for a period of 8 hours,
for 12 hours, for 13 hours, for 14 hours, for 15 hours, for 16 hours, for 18 hours and not more than 24 hours.
[0026] As used herein, a "subject" is any mammal suffering from PD or exhibiting symptoms of PD. A subject can be a primate (e.g., human or macaque) or a rodent (e.g., mouse, rat or guinea pig), but most typically is a human subject. One skilled in the art can readily determine if a subject is suffering from PD or exhibiting PD symptoms by performing a standard clinical or neurological assessment; for example, by using the Unified Parkinson's Disease Rating Scale (UPDRS).
[0027] As used herein, "Parkinson's disease" or "PD" includes PD of any etiology, including idiopathic PD, postencephalitic PD, PD resulting from chronic manganese poisoning or carbon monoxide poisoning, parkinsonism-dementia of Guam and hemiparkinsonism. PD also includes any neurological syndrome of undetermined etiology which a subject presents with neurological symptoms associated with a decrease in dopamine production or dopaminergic transmission in the brain.
[0028] The composition to be used according to the present method has specific requirements with respect to its partial glycine agonist release properties. These properties can be defined in part by pharmacokinetic data for the controlled release composition comprising a partial glycine agonist that can be obtained experimentally, for example, from a statistically relevant number of test subjects according to pre-established and accepted pharmacokinetic protocol. The test subjects herein can be of the same species as the patients, i.e. a human, preferably adult, and preferably including a significant number of test subjects that are representative of the patients currently being treated for PD. The protocol can involve a single dose or once daily dosing for several days, usually at least 3-7 days. A dose,
unit dosage, or doses used to provide pharmacokinetic data in test subjects should be similar to the once daily dose desired to be administered to the patient By "similar" in the present context is meant equivalent, or sufficiently close that, by reasonable interpolation or extrapolation from the data, pharmacokinetic properties for the desired dose can be reasonable estimated.
[0029] It is preferred mat the composition, following single dose administration of 1 to 12 mg/kg D-cycloserine or a therapeutically equivalent dose of a partial glycine agonist other than D-cycloserine per kg body weight, exhibit a maximum plasma concentration (Cmax) of a partial glycine agonist that is not greater than about 30 μg/ml. It is especially preferred that the composition exhibit a pharmacokinetic profile consistent with steady-state plasma concentrations having a fluctuation ratio that is not substantially greater than that of the immediate release formulation of partial glycine agonist. Fluctuation ratio (FR) is defined by the following equation: FR=(Cmax-Cmin)/Cavg, where Cmax, Cmin and Cavg are maximum, minimum and average plasma concentrations respectively.
[0030] A composition having the in vitro release and/or in vivo pharmacokinetic parameters specified above is advantageous in having reduced potential to cause undesirable side effects related to partial glycine agonist toxicity that may be related to a combination of high Cmax and short Tmax, by comparison with other once-daily dosage forms. Preferably, the incidence of side effects is no greater than with an immediate-release dosage form of a partial glycine agonist formulation administered in conjunction with levodopa in a three-five times daily regimen. More preferably, the incidence of levodopa use side effects is even lower than with such an immediate-release partial glycine agonist regimen. It is contemplated that these advantages become more pronounced with increase in daily dosage. In some
embodiments, the partial glycine agonist release profile provides sufficient partial glycine agonist in the brain of the subject to enhance efficacy or reduce the side effects of each levodopa dose concomitantly administered together with or separately of the partial glycine agonist for at least 18 to about 24 hours.
[0031] In some embodiments, the composition administered to PD subjects according to the present method provides a 8-24 hour profile of plasma partial glycine agonist concentration, averaged over the test subjects, that does not substantially exceed 30 μg/mL and does not substantially fall below about 10 μg/mL. It is an objective of the present invention to provide an effective dose of partial glycine agonist during the waking hours of the patient concurrently with levodopa administration. The plasma concentration of the partial glycine agonist during the patient's sleeping hours may deviate from the therapeutic range of approximately 10 μg/mL to 30 μg/mL.
[0032] In some embodiments, the plasma partial glycine agonist concentration neither substantially nor protractedly falls below about 1, about 5, about 7, about 9, or about 10 μg/ml. In various embodiments, the plasma partial glycine agonist concentration neither substantially nor appreciably exceeds about 40, about 37, about 35 or about 30 μg/ml. With respect to the terms "substantially" and "appreciably" in the present context, the following situations are illustrative. A concentration that is within about 20%, for example within about 20%, below a stated minimum or above a stated maximum is considered not to "substantially" fall below or exceed the stated minimum or maximum respectively. A concentration that temporarily falls below a stated minimum or exceeds a stated maximum for a period of less than about 2 hours, for example less than about 1 hour, is considered not to "appreciably" fail below or exceed the stated minimum or maximum respectively.
[0033] In one particular embodiment, the plasma partial glycine agonist concentration, averaged over the test subjects, does not substantially or appreciably fall below about 10 μg/mL and does not substantially or appreciably exceed about 30 μg/mL.
[0034] In some embodiments, the present invention illustratively provides examples of partial glycine agonist release from a controlled release formulation as measured in a standard in vitro dissolution test. The present invention is designed to be formulated with a specific pharmacokinetic profile wherein, with once daily administration of a controlled release formulation of a partial glycine agonist, plasma concentrations of the aforementioned agonist can remain within a narrow window as described above.
For example, the composition will typically be formulated wherein the release of a partial glycine agonist in an effective dose is still occurring at least about 8 hours, for example at least about 10 hours, at least about 12 hours, at least about 14 hours, at. least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, or at least about 24 hours. In some embodiments the pharmaceutical composition upon initial administration of one dose, provides in the subject a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 - 24 hours. The partial glycine agonist can be present in an amount effective to produce a partial glycine agonist concentration in fee brain of a subject at which the partial glycine agonist antagonizes the glycine binding site or acts as a functional antagonist of the NMDA receptor for at least 12 -24 hours.
[0035] Such a release profile is an example of a sustained profile or extended release profile. The terms "extended release", "immediate release", etc., have their commonly accepted meanings used in the field of pharmacy and pharmacokinetics. The kinetics of the extended release can be influenced by the choice of the delivery system, amount of the active ingredient, dissolution rate of the drug, compartment in which release occurs (e.g., with oral delivery systems, this is the gastrointestinal tract), absorption of drug from the site of release into the systemic circulation, drug distribution from the systemic circulation, etc.
[0036] In an illustrative example, a once daily pharmaceutical composition can comprise a partial glycine agonist, wherein the composition also includes a controlled release matrix or coating portion comprising a partial glycine agonist, a sustained release carrier, and at least one pharmaceutically acceptable excipient. The composition upon initial administration of one dose can provide a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of Hie partial glycine agonist of not more than 30 μg/mL for 12 - 18 hours. The partial glycine agonist is present and upon release, the partial glycine agonist dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa.
Pharmaceutical Compositions
[0037] In some embodiments, a once daily pharmaceutical composition for the treatment of PD in a patient is provided. The pharmaceutical composition for the treatment of Parkinson's disease in a subject comprises a controlled release formulation having an immediate release component and a
sustained release component. The formulation is adapted to release a partial glycine agonist according to an in vitro release profile when measured in a standard dissolution test apparatus, i.e. in a U.S.P. type I dissolution apparatus in an acidic pH medium at 100 r.p.m., 37°C, where the immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the total amount of the partial glycine agonist in the composition is released from said sustained release component during a second phase having a duration between 12 to about 24 hours. The partial glycine agonist can be present in an amount effective when administered once daily to enhance the efficacy of levodopa concomitantly administered with or separately or to reduce the frequency or severity of side effects of the levodopa.
[0038] In some embodiments, the controlled release formulation can include one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition can also contain one or more excipients which can include one or more of carriers, wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidant and mixtures or combinations thereof.
[0039] In some embodiments, a controlled release formulation can comprise a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient The composition upon initial administration of one dose can provide a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 - 24 hours. The partial glycine agonist dose present in the composition, when released in the subject, can provide an amount effective to produce
a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor or acts as a functional antagonist of the NMDA receptor for at least 12, or about 14, or about 16, or about 18, or about 20, or about 22, or about 24 hours. In some embodiments, the partial glycine agonist is present in a dose that when made bioavailable in the subject, is effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa.
[0040] In some embodiments, the controlled release partial glycine agonist can be administered in conjunction with levodopa, and can be administered together with the partial glycine agonist or taken separately. The controlled release partial glycine agonist can be taken at the same time as the levodopa or before taking levodopa. In some embodiments, the levodopa can be ingested 1 hour, 2 hours, 3 hours or up to 4 hours after the administration of the controlled release partial glycine agonist. In the practice of the present method, the levodopa and partial glycine agonist can optionally be administered with a peripheral dopa decarboxylase inhibitor, such as carbidopa or benserazide. One skilled in the art can readily determine the amount of peripheral dopa decarboxylase inhibitor to be administered to a subject. In general, 10 mg of carbidopa or 15 mg of benserazide can be given 2-3 times daily with levodopa to the average adult human. Carbidopa or benserazide dosage can be adjusted upward daily until the desired effect is seen. Combined carbidopa/levodopa formulations are available commercially, for example, from Bristol Meyers Squibb Co,, Princeton, N.J., as SinemetRTM.
[0041] In another aspect, the present disclosure provides pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of a partial glycine agonist described above, formulated together with one or more
pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail below, the controlled release pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e. g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension of sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; sublingual; ocular; transdermal; or nasal.
[0042] In some embodiments, the compositions of the present invention comprise one or more controlled release components. In some embodiments, the controlled release properties exhibit an extended or sustained release pharmacokinetic profile. In some embodiments, the compositions may contain one or more controlled release materials, illustratively selected from two formulation components having different release characteristics. Thus a composition can comprise a first formulation component comprising a partial glycine agonist exhibiting a first release profile and a second formulation component comprising the same or different partial glycine agonist exhibiting a second release profile. Illustratively, the first release profile can be an immediate release profile and the second release profile can be an extended or sustained release profile.
[0043] The preparation of controlled release formulations and components are well known within the art. U.S. Patent Nos. 2005/0175691, 2004/0242640, 2003/0219488 and WO 2005/097191 describe exemplary formulations useful for
preparing controlled release formulations of the present invention and are each incorporated by reference herein. In some embodiments, the composition comprises a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for at least 12 hours to about 24 hours. The partial glycine agonist is present in the pharmaceutical composition in a dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa in a Parkinson's subject treated with levodopa.
[0044] In the case of a discrete solid dosage formulation, the immediate and sustained release components can be more or less intimately co-mixed or blended, or alternatively can form spatially distinct zones of the dosage form.
[0045] An illustrative composition has spatially distinct zones comprising a core and a mantle surrounding the core. In such a composition, the mantle can comprise a partial glycine agonist exhibiting an immediate release profile and the core can comprise the same or different partial glycine agonist exhibiting a sustained release profile.
[0046] Another illustrative composition has spatially distinct zones comprising at least two layers. An example of such a composition is a bilayer tablet, wherein one layer, an immediate release component, can comprise a partial glycine agonist exhibiting an immediate release profile and the other sustained release component layer comprises the same or different partial glycine agonist exhibiting an sustained release profile.
[0047] In one embodiment, the composition comprises an immediate release and sustained release formulation components as described above, which comprise particles of a first and second kind respectively. For example, the particles of the first kind can exhibit an immediate release profile and the particles of the second kind can exhibit a sustained release profile. Illustratively, the particles of the second kind comprise a core comprising the partial glycine agonist and a sustained and/or delayed release coating comprising the same or different partial glycine agonist surrounding the core.
[0048] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0049] The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e. g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other components and agents of the formulation and not deleterious to the patient after administration. In some illustratively examples, pharmaceutically-acceptable carriers can include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose
and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; any polyol, such as, but not limited to, glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; (19) ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.
[0050] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0051] Examples of pharmaceutically-acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like. In some embodiments, a formulation of the present disclosure comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e. g., bile acids, and polymeric carriers, e. g., polyesters and polyanhydrides. In some embodiments, an aforementioned formulation renders orally bioavailable a compound of the present disclosure.
[0052] Methods of preparing these formulations or compositions include the step of bringing into association one or more partial glycine agonists with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and mixing with a partial glycine agonist with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges, powders, granules, or as a solution or a suspension in an aqueous or non- aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) each containing an effective amount of a partial glycine agonist as an active ingredient. A controlled release partial glycine agonist formulation of the present disclosure may also be administered as a bolus, electuary or paste.
[0053] In solid dosage forms of the disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches and the like), the partial glycine agonist is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as glycerol and paraffin; absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; lubricants,
such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid; coloring agents; and controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions can also comprise buffering agents. Solid compositions of controlled release partial glycine agonist formulations can also be used as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0054] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0055] The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. In some embodiments, the present controlled release pharmaceutical compositions can be formulated so as to provide immediate, sustained, delayed, pulsed, biphasic release of a partial glycine agonist using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. The compositions may be prepared for immediate release, e.g., freeze-dried. In some embodiments, the compositions can be sterilized
by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. The compositions can also optionally contain opacifying agents and may be of a composition that they release the partial glycine agonist or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The partial glycine agonist can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[0056] The compositions intended for oral use can be prepared according to any method commonly known in the art. The pharmaceutical compositions of the present disclosure can contain one or more agents selected from the group consisting non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. Such excipients include, for example, an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the partial glycine agonist is mixed with an inert diluent and a controlled and/or immediate release matrix or coating.
Liquid Formulations
[0057] Liquid dosage forms for oral administration of the compounds of the disclosure can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the
liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0058] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0059] Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The partial glycine agonist can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellents which may be required.
[0060] The ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0061] Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can
additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstitutεd hydrocarbons, such as butane and propane.
[0062] Transdermal patches have the added advantage of providing controlled delivery of a partial glycine agonist of the present disclosure to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
[0063] Pharmaceutical compositions of the present disclosure can be suitable for parenteral administration comprising a partial glycine agonist in a controlled release formulation in combination with one or more pharmaceutically- acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0064] One skilled in the art can readily prepare pharmaceutical compositions comprising a partial glycine agonist, for example by using the principles set forth in Remington's Pharmaceutical Science, 18th Edition (Alphonso Gennaro, ed.), Mack Publishing Co., Easton, Pa, 1990. Preferred pharmaceutical compositions of the present disclosure comprise a partial glycine agonist in a controlled release form.
[0065] The compositions of the present disclosure may be given enterally, illustratively orally, parenterally, topically, or rectally. They are of course provided in forms suitable for each administration route. For example, they can be administered in
tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
[0066] These the controlled release formulation of a partial glycine agonist may be administered to humans and other animals, including rats, mice, rabbits , dogs, cats, non-human primates, and monkeys for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually. Regardless of the route of administration selected, the compounds of the present disclosure, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
[0067] In general, a suitable daily dose of a partial glycine agonist contained within a controlled release formulation will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect i.e. a dose which produces a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor. In some embodiments, an effective dose can be a dose of a partial glycine
agonist wherein the plasma levels of the partial glycine agonist in the patient is between about lOμg/raL and about 30 μg/mL for at least about 12 hours to at least about 24 hours. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, and subcutaneous doses of the controlled release partial glycine agonist of the present disclosure for a patient, when used for the desired thereapeutic effects, will range from about 1 to about 12 mg per kilogram of body weight per dose of D-cycloserine or a therapeutically equivalent amount of partial glycine agonist other than D-cycloserine. In some embodiments, the dosage of partial glycine agonist can be about 1 mg to about 12 mg of D-cycloserine per kg body weight of the subject per dose or equivalents thereof.
[0068] In some embodiments, the once daily pharmaceutical composition containing the controlled release partial glycine agonist formulation can be concomitantly administered with at least one dose of levodopa. In some embodiments, the effective daily dose of levodopa may be administered as two, three, four, or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing for the levodopa is one or more administrations per day, optionally in combination with carbidopa and/or a peripheral dopa carboxylase such as benserazide.
In some embodiments, the present disclosure provides pharmaceutically acceptable compositions which comprise a controlled release formulation adapted to release a partial glycine agonist according to a single sustained release profile or a dual profile having two different release component phases of dissolution when measured in a U.S.P. type I dissolution apparatus in an acidic pH medium at 100 r.p.m., 37°C, where the immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the
total amount of the partial glycine agonist in the composition is released from the sustained release component during a second phase having a duration between 12 to about 24 hours;
[0069] The partial glycine agonist is administered in a dose effective to enhance the efficacy of levodopa or to reduce the frequency or severity of side effects of the levodopa,
[0070] In some embodiments a method is provided for treating Parkinson's disease in a patient comprising: administering levodopa to the patient at least once per day; and administering to the patient a once daily composition comprising a single unit dose partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose administered together with or separately for up to 18 hours after administration of the partial glycine agonist.
[0071] Increasing the duration of effect of a levodopa dose with a therapeutic dose of a controlled release partial glycine agonist allows one to give fewer levodopa doses, avoid side effects, reduce the severity of the side effects of levodopa, or to reduce the levodopa standard dose, but still achieve the same therapeutic effect. This is particularly advantageous, because giving fewer or reduced levodopa doses to a subject with PD delays the point at which levodopa becomes ineffective.
[0072] Administering a pharmaceutical composition comprising a controlled release formulation of partial glycine agonist also reduces the frequency or severity of levodopa-induced side effects, such as dyskinesias and dystonias.
[0073] One skilled in the art can readily determine whether the frequency or severity of levodopa-induced dyskinesias is reduced by using any suitable technique for the clinical assessment of involuntary movements in subjects with PD. For example, the frequency and severity of levodopa-induced dyskinesias can be assessed using the Abnormal Involuntary Movement Scale (AIMS) or similar rating of dyskinesia.
[0074] For example, assessment of subjects undergoing levodopa therapy with high dose partial glycine agonist are subjected to a six-week trial. During the trial, subjects fill out a detailed diary with regard to the frequency or duration of dyskinesias and severity of any dyskinesias and assess daily function according to the following scales: Dyskinesia Intensity: 0-without dyskinesia; 1-mild dyskinesia; 2- medium dyskinesia; 3-severe dyskinesia. Rating of Daily Function: 1-improvement of daily function as compared to the basic condition; 2-no improvement in daily function; 3-deterioration of daily function as compared to the basic condition.
[007S] A reduction in the daily AIMS scores duration of dyskinseias during the course of the trial indicates that the frequency and severity of dyskinesias are being reduced. Alternatively, AIMS scores obtained after administration of levodopa and high dose partial glycine agonist to a subject can be compared to AIMS (or similar test) scores obtained for the subject prior to treatment with high dose partial glycine agonist.
[0076] One skilled in the art can also readily determine whether the frequency or severity of levodopa-induced dystonias is reduced by using any suitable technique for the clinical assessment of involuntary, sustained muscle contraction in subjects with PD. For example, frequency or severity of dystonias can be determined
by clinical observation of the subject, including reflex studies, or by techniques such as electromyography (EMG) or nerve conduction velocity tests.
[0077] The present disclosure also provides a method for increasing the therapeutic index of levodopa in a subject being treated for Parkinson's disease, comprising administering levodopa and a pharmaceutical composition comprising a controlled release formulation comprising partial glycine agonist in an effective dose to the subject.
[0078] As used herein, "therapeutic index" refers to a quantitative measure of the selectivity of a drug when a therapeutic effect ("E") and a toxic effect ("T") are being compared. The therapeutic index can then be calculated as ED50/TD50, at some arbitrary level of response observed in a subject receiving the drug. The ED50 is the dose required to generate the desired intensity of therapeutic effect in 50% of the subjects tested. The TD50 is the dose required to generate the toxic effect in 50% of the subjects tested.
[0079] The therapeutic index is a useful indicator of the benefit versus adverse effect of a drug. Those drugs which have a high therapeutic index can be administered over a wide range of effective doses without incurring significant adverse events. Conversely, drugs having a small therapeutic index can be administered over a small range of effective doses without incurring significant adverse events. The therapeutic index of levodopa lessens over time with chronic administration.
[0080] As discussed above, a pharmaceutical composition comprising a controlled release formulation of partial glycine agonist can increase the efficacy of levodopa while also reducing toxic side effects. Thus, the therapeutic index of levodopa is increased by administration of a controlled release dose of a partial
glycine agonist over a period of 12 to about 24 hours. As discussed above, techniques for determining whether the efficacy of levodopa has increased, and whether toxic side effects of levodopa have been reduced, are within the skill in the art. Suitable effective doses of the partial glycine agonist and suitable routes of administration are as described above.
[0081] Substances which inhibit peripheral dopa decarboxylase (e.g., carbidopa or benserazide) can also be administered to the subject with levodopa in order to increase the therapeutic index of levodopa.
[0082] In another embodiment, the present disclosure provides a method of treating PD in a subject, comprising administering to a subject in need of such treatment a partial glycine agonist in a controlled release formulation having an immediate release component and a sustained release component. Without wishing to be bound by theory, it is believed that altered NMDA receptor transmission can be involved in abnormal basal ganglia activity in PD and is involved in levodopa-related treatment complications such as wearing off and dyskinesia. Partial glycine agonists acting as non-selective antagonists of the NMDA receptor can correct this altered NMDA receptor transmission. Suitable and effective doses of the partial glycine agonist and suitable routes of administration are as described above.
[0083] The present disclosure also provides a kit comprising a controlled release formulation comprising a partial glycine agonist and instructions for administering a sustained release or biphasic release profile of the partial glycine agonist to a subject suffering from PD. The instructions can specify mat the partial glycine agonist is administered with or without levodopa. Preferably, the instructions specify that the partial glycine agonist is administered with levodopa, and that more than one dose of levodopa per day is required to maintain thereapeutic benefit of the
levodopa. The instructions can also specify that the partial glycine agonist can. be administered with a peripheral dopa decarboxylase inhibitor such as carbidopa or benserazide.
[0084] In one embodiment, the kit further comprises levodopa. in another embodiment, the kit further comprises levodopa and a peripheral dopa decarboxylase inhibitor. Preferably, the kit comprises a controlled release formulation comprising partial glycine agonist and levodopa in separate pharmaceutical compositions, in which the amount of partial glycine agonist is sufficient to sustain a plasma level of 10, 15, 20, 25, or 30 μg/mL partial glycine agonist while the patient is awake for at least 12 hours but no more than 16 hours within a 24 hour period. For example, the single-dose pharmaceutical composition can deliver at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg or at least 8 mg/kg, for example 8 to 12 mg/kg, partial glycine agonist to the subject over a period of at least 12 hours and generally no more than 24 hours maintaining the plasma concentration of partial glycine agonist in the subject constant or in a dual (immediate and sustained) release profile wherein there is a spike in the concentration of the partial glycine agonist wherein 0-30 % of the total dose of the partial glycine agonist is released in the first 60 minutes and the balance of the total partial glycine agonist present is released in a constant and sustained fashion over a period of 11 to 23 hours.
[0085] Additional embodiments, as well as features, benefits and advantages, of the present invention will be apparent to those skilled in the art, taking into account the foregoing description of preferred embodiments of the invention. It is therefore to be appreciated that the present invention is not to be construed as being ion any way limited by the foregoing description of such preferred embodiments, but
that various changes and modifications can be made to the invention as specifically described herein, and that all such changes and modifications are intended to be within the scope of the present invention.
Claims
1. A pharmaceutical composition for the treatment of Parkinson's disease in a subject said composition comprising: a controlled release formulation having an immediate release component and a sustained release component, said formulation is adapted to release a partial glycine agonist according to an in vitro release profile when measured in a standard dissolution test apparatus, where said immediate release component is formulated to release 0 to about 30% of the partial glycine agonist in the composition within about 1 hour and the balance of the total amount of the partial glycine agonist in the composition is released from said sustained release component during a second phase having a duration between 12 to about 24 hours, wherein the partial glycine agonist is present in an amount effective when administered once daily to enhance the efficacy of levodopa concomitantly administered or to reduce the frequency or severity of side effects of the levodopa; said controlled release formulation further comprising one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition of claim 1, wherein the partial glycine agonist is selected from the group consisting of D-cycloserine, 1- aminocyclopropanecarboxylic acid and (+)-3-Amino-1-hydroxypyrrolidin-2-one.
3. The pharmaceutical composition of claim 2, wherein the partial glycine agonist is D-cycloserine.
4. The pharmaceutical composition of claim 1, wherein the effective dose of the partial glycine agonist is sufficient to deliver greater than about 1 mg to about 12 mg of partial glycine agonist per kg body weight of the subject.
5. The pharmaceutical composition of claim 4, wherein the effective dose of partial glycine agonist administered is sufficient to maintain the subject with a blood plasma level of more than 10 μg/mL and less than 30 μg/mL over a 18 hour period.
6. The pharmaceutical composition of claim 4, wherein the effective dose of a controlled release partial glycine agonist is a dose which produces a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor or acts as a functional antagonist of the NMDA receptor.
7. The pharmaceutical composition of claim 5, wherein the 18 hour period comprises a period during which the subject is awake.
8. The pharmaceutical composition of claim 1, wherein the composition is formulated for enteral or parenteral administration, said composition is selected from the group consisting of an aqueous or oily suspension, emulsions, microemulsions, suspensions, tablet, gel capsule, dispersible powders or granules, emulsions, hard or soft capsules, syrups, eleixirs, suppositories, liposome preparation, microencapsulation preparation, transdermal patch and sprays.
9. The pharmaceutical composition of claim 1 , wherein the composition includes one or more excipients selected from the group consisting of carriers, wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants and combinations thereof.
10. A pharmaceutical composition for the treatment of Parkinson's disease, said composition comprising: a controlled release formulation comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 through 24 hours, the partial glycine agonist is present in an amount effective to produce a partial glycine agonist concentration in the brain of a subject at which the partial glycine agonist antagonizes the glycine binding site of the NMDA receptor for at least 12 through 24 hours.
11. The pharmaceutical composition of claim 10, wherein the partial glycine agonist is selected from the group consisting of D-cycloserine, 1- aminocyclopropanecarboxylic acid and (+)-3-Amino-1-hydroxypyrrolidin-2-one.
12. The pharmaceutical composition of claim 11, wherein the partial glycine agonist is D-cycloserine.
13. The pharmaceutical composition of claim 10, wherein the amount of the partial glycine agonist is sufficient to deliver a unit dose greater than about 1 mg/kg to about 12 mg/kg of D-cycloserine or a therapeutically equivalent unit dose of a partial glycine agonist other than D-cycloserine per kg body weight of the subject.
14. The pharmaceutical composition of claim 13, wherein the amount of partial glycine agonist present in said composition is sufficient to maintain the subject with a blood plasma level of more than 10 μg/mL and less than 30 μg/mL over a 24 hour period.
15. The pharmaceutical composition of claim 14, wherein the 24 hour period comprises a period during which the subject is awake.
16. The pharmaceutical composition of claim 10, wherein the composition is formulated for enteral or parenteral administration, said composition is selected from the group consisting of an aqueous or oily suspension, tablet, gel capsule, dispersible powders or granules, emulsions, hard or soft capsules, syrups, eleixirs, suppositories, liposome preparation, microencapsulation preparation, transdermal patch and sprays.
17. The pharmaceutical composition of claim 1, wherein the composition further comprises one or more agents selected from the group consisting of carriers, wetting agents, emulsifiers, lubricants, coloring agents, release agents, coating agents, sweetening, flavoring arid perfuming agents, preservatives and antioxidants and combinations thereof.
18. A method for treating Parkinson's disease in a subject comprising;
(a) administering levodopa to the patient at least once per day; and
(b) administering to the subject a once daily composition comprising a partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose concomitantly administered together with or separately for at least 18 to about 24 hours after administration of the partial glycine agonist.
19. The method of claim 18, wherein the partial glycine agonist is selected from the group consisting of D-cycloserine, 1-aminocyclopropanecarboxylic acid and (+)- 3-Amino-1-hydroxypyrrolidin-2-one.
20. The method of claim 19, wherein the partial glycine agonist is D-cycloserine.
21. The method of claim 18, further comprising administering a peripheral dopa decarboxylase inhibitor to the subject.
22. The method of claim 18, wherein the levodopa or partial glycine agonist is administered enterally.
23. The method of claim 18, wherein the levodopa or partial glycine agonist is administered parentally.
24. The method of claim 18, wherein the dose is sufficient to deliver greater than about 1 mg to about 12 mg of partial glycine agonist per kg body weight of the subject.
25. The method of claim 18, wherein the levodopa side effects are dyskinesias, dystonias, deterioration of daily function, depression, and anxiety.
26. The method of claim 18, wherein the subject is selected from the group consisting of humans, non-human primates, monkeys and rodents.
27. The method of claim 27, wherein the subject is human.
28. A kit comprising: a partial glycine agonist in a controlled release formulation; and instructions for administering a high dose of a partial glycine agonist to a subject for the treatment of Parkinson's disease.
29. The kit of claim 29, further comprising instructions for administering the partial glycine agonist in combination with levodopa for the treatment of Parkinson's disease.
30. The kit of claim 28, wherein the kit further comprises levodopa.
31. The kit of claim 28, wherein the partial glycine agonist is selected from the group consisting of D-cycloserine, 1-aminocyclopropanecarboxylic acid and (+)-3- Amino-1-hydroxypyrrolidin-2-one.
32. The kit of claim 28, further comprising a peripheral dopa decarboxylase inhibitor.
33. The kit of claim 32, wherein the peripheral dopa decarboxylase inhibitor is carbidopa or benserazide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US151507P | 2007-11-01 | 2007-11-01 | |
US61/001,515 | 2007-11-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009059242A1 true WO2009059242A1 (en) | 2009-05-07 |
WO2009059242A8 WO2009059242A8 (en) | 2009-07-16 |
Family
ID=40591504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/082139 WO2009059242A1 (en) | 2007-11-01 | 2008-10-31 | A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009059242A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015069773A1 (en) | 2013-11-05 | 2015-05-14 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
CN111643493A (en) * | 2020-05-26 | 2020-09-11 | 上海京新生物医药有限公司 | High-concentration levodopa preparation and preparation method and application thereof |
US20220047560A1 (en) * | 2018-09-13 | 2022-02-17 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040186105A1 (en) * | 2002-08-30 | 2004-09-23 | Allenspach Carl T. | Pharmaceutical composition exhibiting consistent drug release profile |
US20060173064A1 (en) * | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
US20070129412A1 (en) * | 2002-09-13 | 2007-06-07 | Thomas Jefferson University | Methods for treating parkinson's disease |
-
2008
- 2008-10-31 WO PCT/US2008/082139 patent/WO2009059242A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060173064A1 (en) * | 2001-08-24 | 2006-08-03 | Lippa Arnold S | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders |
US20040186105A1 (en) * | 2002-08-30 | 2004-09-23 | Allenspach Carl T. | Pharmaceutical composition exhibiting consistent drug release profile |
US20070129412A1 (en) * | 2002-09-13 | 2007-06-07 | Thomas Jefferson University | Methods for treating parkinson's disease |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3065808A4 (en) * | 2013-11-05 | 2017-08-16 | SynAgile Corporation | Devices and methods for continuous drug delivery via the mouth |
JP2022130379A (en) * | 2013-11-05 | 2022-09-06 | シンアジャル コーポレイション | Devices and methods for continuous drug delivery via mouth |
WO2015069773A1 (en) | 2013-11-05 | 2015-05-14 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
US11426376B2 (en) | 2015-05-06 | 2022-08-30 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
US9901561B2 (en) | 2015-05-06 | 2018-02-27 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10300033B2 (en) | 2015-05-06 | 2019-05-28 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10328044B2 (en) | 2015-05-06 | 2019-06-25 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10588882B2 (en) | 2015-05-06 | 2020-03-17 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10786474B2 (en) | 2015-05-06 | 2020-09-29 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US11135191B2 (en) | 2015-05-06 | 2021-10-05 | Synagile Corporation | Devices for the administration of pharmaceutical suspensions |
US20220047560A1 (en) * | 2018-09-13 | 2022-02-17 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
CN111643493A (en) * | 2020-05-26 | 2020-09-11 | 上海京新生物医药有限公司 | High-concentration levodopa preparation and preparation method and application thereof |
CN111643493B (en) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | High-concentration levodopa preparation and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2009059242A8 (en) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210401777A1 (en) | Methods and compositions for treating sleep apnea | |
US7160913B2 (en) | Methods and kit for treating Parkinson's disease | |
EP1066038B1 (en) | Use of cabergoline in the treatment of restless legs syndrome | |
TWI353835B (en) | Novel methods for identifying improved, non-sedati | |
EP1082292B1 (en) | Control of pain with endogenous cannabinoids | |
US20040248979A1 (en) | Method of treating lower urinary tract disorders | |
CN111670050A (en) | Methods and compositions for treating sleep apnea | |
JP2009517393A (en) | How to treat anxiety | |
JP2007533691A (en) | Α-Aminoamide derivatives useful for the treatment of restless leg syndrome and addictive disorders | |
US20210401790A1 (en) | Methods and compositions for treating sleep apnea | |
SK287180B6 (en) | Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments | |
WO2009059242A1 (en) | A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use | |
US20100081626A1 (en) | Weight loss compositions and uses thereof | |
PT1628652E (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
CA2590883A1 (en) | Medicinal composition for treating diabetes | |
JP5850299B2 (en) | Obsessive-compulsive disorder treatment | |
AU2003267557B2 (en) | Treatment of dyskinesia | |
JP2017052778A (en) | Tapentadol for treating pain associated with trigeminal neuralgia | |
US7786126B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
JP2003512428A (en) | Treatment of dyskinesia | |
AU2001263042A1 (en) | R-eliprodil for treating glaucoma | |
US20090298895A1 (en) | Use of thioproline in body weight reduction treatments | |
AU2004268381A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
WO2023210617A1 (en) | Pharmaceutical composition for treatment of parkinson's disease | |
US20190274974A1 (en) | Treatment of Pain Associated with Trigeminal Neuralgia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08846073 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 08846073 Country of ref document: EP Kind code of ref document: A1 |